Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMX

0.00
  • Immix outlined its NXC-201 BCMA-targeted CAR-T program for relapsed or refractory AL amyloidosis, highlighting a lack of FDA-approved therapies in this setting.
  • Company materials cited a 95% complete response rate for NXC-201 in NEXICART-2, versus 0-10% for current investigator’s-choice regimens.
  • Regulatory positioning highlighted FDA Breakthrough Therapy Designation in January 2026, RMAT in February 2025, Orphan Drug Designation in September 2023.
  • Development timeline showed NEXICART-2 enrollment completion at 45 patients in March 2026, with the next update slated for late September 2026.
  • Planned BLA submission targeted 1H 2027, with a commercial launch plan tied to approval in 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.